Genoa

• Safety, efficacy and pharmacokinetics of sparsentan in pediatric subjects with selected kidney diseases. Recruiting
  2023-505497-14-00 4 2021-12-09 Proteinuric glomerular diseases including: •Focal segmental glomerulo
• SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years. Recruiting
  2024-510578-25-00 5 2021-11-05 Histologically proven high-risk medulloblastoma, with any of the curre
• A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis an … Recruiting
  2023-505825-15-00 4 2021-10-29 Lupus Nephritis (LN)
• A Randomized & Observational phase II trial comparing the activity of TrabectedIn vs gemCitabine in patients with metastatic or locally adva … Recruiting
  2024-513820-40-00 4 2021-10-29 Metastatic or locally advanced leiomyosarcoma
• Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasth … Recruiting
  2024-513854-31-00 10 2021-10-27 Generalized Myasthenia Gravis
• Apremilast Study in Children with Active Juvenile Psoriatic Arthritis Recruiting
  2023-503435-17-00 5 2021-03-31 Juvenile psoriatic arthritis
• Radiation-Free Therapy for the Initial treatment of Good prognosis early non-bulky HL, defined by a low Metabolic Tumor Volume and a negativ … Recruiting
  2024-515063-66-00 4 2021-03-30 Early stage classical Hodgkin Lymphoma (cHL) without bulky lesions and
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• “A phase II, single arm study investigating neoadjuvant plus adjuvant treatment with Cemiplimab in surgically resectable, high risk stage II … Recruiting
  2024-515204-39-00 4 2021-02-10 surgically resectable, high risk stage III/IV (M0) Cutaneaous Squamous
• ExclUsive endocRine therapy Or radiation theraPy for women aged ≥70 years with luminal A-like early stage breast cancer (EUROPA): a randomiz … Recruiting
  2023-508094-88-00 5 2021-02-08 breast cancer
• Induction and maintenance treatment with PARP inhibitor and immunotherapy in HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC). PRI … Recruiting
  2024-516798-54-00 4 2021-02-08 HPV-negative Head and Neck Squamous Cell Carcinoma (HNSCC)
• “A phase II randomized non-comparative study, with NEOadjuvant plus adjuvant Therapy with combination or sequence of vemurafenib, cobImetini … Recruiting
  2024-516659-41-00 4 2020-10-12 high-risk, surgically resectable BRAF mutated and wild-type Melanoma
• FaR-RMS: An overarching study for children and adults with Frontline and Relapsed RhabdoMyoSarcoma Recruiting
  2024-510579-40-00 9 2020-10-07 Rhabdoyosarcoma
• RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line … Recruiting
  2024-518623-30-00 6 2020-10-01 metastatic castration resistant prostate cancer without mutations of B
• Study aimed at comparing the impact on long-term neurocognitive development of the use of low dose sevoflurane, dexmedetomidine and remifent … Recruiting
  2024-512385-34-00 5 2020-09-30 Children under the age of 2 years having surgery lasting at least 2 ho
• Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels, in adult … Recruiting
  2023-510433-29-00 5 2020-09-24 Favorable-intermediate-risk Acute Myeloid Leukemia
• A study evaluating the safety and efficacy of ponatinib for the treatment of recurrent or refractory leukemias or solid tumors in children Recruiting
  2023-509699-41-00 9 2019-11-22 Recurrent or Refractory Leukemias, Lymphomas, and Solid Tumors
• A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With sJIA Recruiting
  2023-507883-38-00 5 2019-11-18 Systemic Juvenile Idiopathic Arthritis
• Trial aimed at examinate the functionality and effectiveness of the drug "IO" in adult patients with a rare form of cancer that affect the c … Recruiting
  2023-510516-39-00 4 2019-10-30 Acute B-cell Lymphoblastic Leukemia with minimal residual positive dis
• Palbociclib plus fulvestrant in women with hormone receptor positive and human epidermal growth factor receptor type 2 negative locally adva … Recruiting
  2024-513372-18-00 4 2019-10-18 Pre- and post-menopausal women with HR+/HER2- LABC or MBC whose diseas
• Phase 2a Study of Luspatercept in Pediatric Participants With Beta (β)-Thalassemia Recruiting
  2022-502499-22-00 4 2019-10-15 Beta (β) Thalassemia
• Phase 3, Open-label Apremilast Pediatric Long-term Extension Study in Children with Oral Ulcers Associated With Behçet’s Disease or Juvenile … Recruiting
  2023-503433-21-00 5 2019-10-03 Behçet’s disease is a chronic, relapsing, multisystem inflammatory dis
• A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic Arthritis (JUVE-X) Recruiting
  2023-506131-15-00 5 2019-09-10 Juvenile Idiopathic Arthritis
• LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma Recruiting
  2023-508101-24-00 5 2019-08-01 Lymphoblastic lymphoma

Showing 337–360 of 660 trials